electroCore, Inc.
ECOR
View Detailed Chart
4.970USD
-0.025-0.50%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
37.11MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.50%
5 Days
+4.85%
1 Month
0.00%
6 Months
-37.95%
Year to Date
-69.34%
1 Year
-17.18%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
21.080
Target Price
+322.02%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 193.09% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 25.18M.
Overvalued
The company’s latest PE is -3.12, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 3.54M shares, increasing 20.60% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 232.33K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.69.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
Ticker SymbolECOR
CompanyelectroCore, Inc.
CEOMr. Daniel S. Goldberger
Websitehttps://www.electrocore.com/
Related Instruments
+1.10%
-0.32%
-0.51%
-0.30%
-0.68%
+0.10%
-0.68%
-10.99%
-0.71%
-0.80%
-0.09%
-0.05%
-0.49%
+1.41%
-0.89%
-2.81%
-0.82%
-0.89%
-1.01%
+14.84%
